JO3239B1 - تركيبات جالينية من مركبات عضوية - Google Patents

تركيبات جالينية من مركبات عضوية

Info

Publication number
JO3239B1
JO3239B1 JOP/2009/0348A JOP20090348A JO3239B1 JO 3239 B1 JO3239 B1 JO 3239B1 JO P20090348 A JOP20090348 A JO P20090348A JO 3239 B1 JO3239 B1 JO 3239B1
Authority
JO
Jordan
Prior art keywords
minutes
dose combination
organic compounds
fixed dose
pharmaceutical oral
Prior art date
Application number
JOP/2009/0348A
Other languages
English (en)
Inventor
Frank Wagner Robert
Valazza Stephen
Vippagunta Sudha
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3239(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3239B1 publication Critical patent/JO3239B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

يتعلق الاختراع الحالي بتركيبة جرعة فمية ثابتة صيدلية تتضمن أ‌) مقدار فعال علاجيا من اليسكيرين ، او ملح مقبول صيدليا، و يفضل ملح نصف فيومارات منه ب‌) مقدار فعال علاجيا من اميلوديبين، او ملح مقبول صيدليا منه، و يفضل ملح نصف فيومارات منه حيث توضح تركيبة الجرعة الثابتة الفمية الصيدلية ذوبان للمكونات في المعمل (أ) من 60% او اقل بعد 10 دقائق و 98% او اقل بعد 20 دقيقة ، و جانب ذوبان من مكونات (ب) من 50% او اكثر بعد 20 دقيقة ، و 70% او اكثر بعد 30 دقيقة عند اس هيدروجيني 2، حيث تكون تركيبة الجرعة الثابتة الفمية الصيدلية المذكورة مكافئة حيويا ، او قريبة من التكافؤ الحيوي ، الى جرعة حرة من اليسكيرين و املوديبين.
JOP/2009/0348A 2008-09-22 2009-09-17 تركيبات جالينية من مركبات عضوية JO3239B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22

Publications (1)

Publication Number Publication Date
JO3239B1 true JO3239B1 (ar) 2018-03-08

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0348A JO3239B1 (ar) 2008-09-22 2009-09-17 تركيبات جالينية من مركبات عضوية

Country Status (21)

Country Link
US (1) US8613949B2 (ar)
EP (1) EP2328564A2 (ar)
JP (2) JP2012503020A (ar)
KR (1) KR20110060942A (ar)
CN (1) CN102159195A (ar)
AR (1) AR073384A1 (ar)
AU (1) AU2009292908B2 (ar)
BR (1) BRPI0919350A2 (ar)
CA (1) CA2736257A1 (ar)
CL (1) CL2011000594A1 (ar)
CO (1) CO6351711A2 (ar)
EC (1) ECSP11010999A (ar)
IL (1) IL211571A0 (ar)
JO (1) JO3239B1 (ar)
MA (1) MA32719B1 (ar)
MX (1) MX2011002988A (ar)
MY (1) MY153610A (ar)
PE (1) PE20110293A1 (ar)
RU (2) RU2011115712A (ar)
TW (1) TW201016217A (ar)
WO (1) WO2010033954A2 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (en) * 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
WO2003097098A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
MX366895B (es) * 2004-11-05 2019-07-30 Boehringer Ingelheim Int Gmbh Star Comprimido bicapa que comprende telmisartán y amlodipina.
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
NZ577320A (en) * 2006-11-07 2012-01-12 Novartis Ag CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide

Also Published As

Publication number Publication date
RU2014140552A (ru) 2015-06-20
CL2011000594A1 (es) 2011-08-05
KR20110060942A (ko) 2011-06-08
WO2010033954A3 (en) 2010-10-21
MA32719B1 (ar) 2011-10-02
EP2328564A2 (en) 2011-06-08
US8613949B2 (en) 2013-12-24
MX2011002988A (es) 2011-04-11
JP2015091830A (ja) 2015-05-14
BRPI0919350A2 (pt) 2015-12-29
AU2009292908B2 (en) 2012-07-26
TW201016217A (en) 2010-05-01
RU2011115712A (ru) 2012-10-27
ECSP11010999A (es) 2011-06-30
CA2736257A1 (en) 2010-03-25
WO2010033954A2 (en) 2010-03-25
MY153610A (en) 2015-02-27
AR073384A1 (es) 2010-11-03
CN102159195A (zh) 2011-08-17
JP2012503020A (ja) 2012-02-02
AU2009292908A1 (en) 2010-03-25
CO6351711A2 (es) 2011-12-20
PE20110293A1 (es) 2011-05-17
IL211571A0 (en) 2011-05-31
US20110165240A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
TN2010000135A1 (en) Galenical formulations of organic compounds
MX2010003439A (es) Combinacion farmaceutica de aliskiren y valsartan.
PT2046298T (pt) Forma de dosagem farmacêutica contendo uma composição solubilizante farmaceuticamente aceitável
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
RS52457B (en) POWDER FORMULATION FOR VALGANCICLOVIR
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0925315B8 (pt) composição farmacêutica de dosagem fixa, oral, sólida, estável na forma de um comprimido de monocamada, processo para a preparação da mesma e uso de irbesartan e besilato de amlodipina
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
CY1113140T1 (el) Στερεα μορφη δοσης απο του στοματος, που περιεχει τον αντιαιμοπεταλιακο παραγοντα κλοπιδογρελη, και μεθοδος για την παρασκευη αυτης
TN2011000100A1 (en) Galenical formulations of organic compounds
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
TW200833375A (en) Pharmaceutical compositions
WO2010044108A3 (en) Controlled release formulations of ropinirole
TH127122A (th) สูตรตำรับยาปรุงของอะลิสไคเรนและแอมโลดินีน